Le Lézard
Classified in: Health, Science and technology, Business
Subjects: EARNINGS, Conference Call, Webcast

Xeris Biopharma to Report First Quarter 2024 Financial Results on May 9, 2024


Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients' lives by developing and commercializing innovative products across a range of therapies, today announced that the Company will release its first quarter 2024 financial results before the open of the U.S. financial markets on Thursday, May 9, 2024. Management will host a conference call and webcast at 8:30 a.m. Eastern Time that day to discuss the Company's financial and operational results.

To pre-register for the call, please go to the following link: https://www.netroadshow.com/events/login?show=7144015a&confId=62782

After registering, a confirmation email will be sent, including dial-in details and a unique code for entry. The Company recommends registering a minimum of ten minutes prior to the start of the call. Following the conference call, a replay will be available until Thursday, May 23, 2024 at US: 1 929 458 6194, US Toll Free: 1 866 813 9403, UK: 0204 525 0658, Canada: 1 226 828 7578, or all other locations: +44 204 525 0658 Access Code: 952508

To join the webcast, please visit "Events" on investor relations page of the Company's website at www.xerispharma.com or use this link: https://events.q4inc.com/attendee/702822810

About Xeris

Xeris (Nasdaq: XERS) is a growth-oriented biopharmaceutical company committed to improving patients' lives by developing and commercializing innovative products across a range of therapies. Xeris has three commercially available products; Gvoke®, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis®, for a proven therapy for primary periodic paralysis, and Recorlev® for the treatment of endogenous Cushing's syndrome. Xeris also has a pipeline of development programs to extend the current marketed products into important new indications and uses and bring new products forward using its proprietary formulation technology platforms, XeriSoltm and XeriJect®, supporting long-term product development and commercial success.

Xeris Biopharma Holdings is headquartered in Chicago, IL. For more information, visit www.xerispharma.com, or follow us on X, LinkedIn, or Instagram.


These press releases may also interest you

at 22:32
CHICANE CAPITAL II CORP. ANNOUNCES FILING OF FINAL PROSPECTUS FOR ITS INITIAL PUBLIC OFFERING
CHICANE CAPITAL II CORP. (the "Corporation") is pleased to announce the filing of a final prospectus for its initial public offering. Access to the prospectus and any amendment thereto is provided in connection with the Corporation's initial public...

at 22:00
NEC Leverages RISE with SAP and AI to Build Business AI in Move to the Cloud
SAP SE today announced NEC Corporation (TSE: 6701 "NEC") has selected SAP S/4HANA Cloud through the RISE with SAP solution, running on Amazon Web Services (AWS). Together with implementation partner ABeam Consulting, the migration will leverage...

at 21:35
Foundry 415 Innovation Group Launches Startup BoostCamp: A Workshop Series to Accelerate Startup Growth and Success
Foundry 415 Innovation Group has unveiled its new Startup BoostCamp workshop series designed to empower startups with the knowledge and strategies they need to overcome the most common challenges to scaling and achieving success in the US market....

at 21:05
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Primerica, Inc. - PRI
Pomerantz LLP is investigating claims on behalf of investors of Primerica, Inc. ("Primerica" or the "Company") .  Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.  ...

at 21:01
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sage Therapeutics, Inc. - SAGE
Pomerantz LLP is investigating claims on behalf of investors of Sage Therapeutics, Inc. ("Sage" or the "Company") .  Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980....

at 21:00
ZIMLog Unveils Transformed Structure and Expanded Scope Pioneering the Future of Logistics with reliable and Personalized Precision
ZIMLog, a global freight forwarding brand, proudly unveils its renewed structure, reflecting a blend of experience and innovation aimed at meeting the diverse and evolving needs of businesses worldwide. After more than 22 years of successful...

More news about Business...


News published on and distributed by: